台灣外科醫學會雜誌

中文 | ENG

	第58卷第2期 2025-3 Predatory publisher and low standard journal: An emerging problem in clinical surgery field
.........................
	第58卷第2期 2025-3 Conflict of interest in clinical surgery: Contemporary concern in digital era
.........................
	第58卷第2期 2025-3 Postpublication redecision and pitfalls of inadequate standards in scientific surgical journals: Important consideration in academic publication
.........................
	第58卷第2期 2025-3 Spontaneous bilateral basal ganglia hemorrhage
.........................
	第58卷第2期 2025-3 Academic characterization of the Formosan Journal of Surgery: A five-year bibliometric analysis
.........................
	第58卷第2期 2025-3 Supra-sternal reconstruction for a high-hanging fruit like right subclavian artery aneurysm
.........................
	第58卷第2期 2025-3 Operations for choledochal cysts: A 25-year experience at a tertiary care center in India
.........................
	第58卷第2期 2025-3 A case report: Can a titanised polypropylene mesh (TiMesh) obviate a dual mesh for sandwich technique for parastomal hernias?
.........................
	第58卷第2期 2025-3 Recurrent gallstone ileus, a deadly encounter: A case report
.........................
	第58卷第2期 2025-3 The changes in dietary intake and tolerance for Chinese food after bariatric surgery in Taiwan
.........................
	第58卷第2期 2025-3 Diagnostic value of trans-recto-perineal ultrasound in perianal fistula—preoperative versus intraoperative findings: A comparative cross-section study
.........................
	第58卷第2期 2025-3 Efficacy and safety of extended-release dinalbuphine sebacate for postoperative analgesia: A systematic review and meta-analysis
.........................
	第58卷第2期 2025-3 Dynamic changes in segmented neutrophil-to-monocyte ratio in trauma patients with stress-induced hyperglycemia: A retrospective study
.........................
	第58卷第1期 2025-1 Ensuring authorship qualification in clinical research articles: A focus on surgical therapy studies
.........................
	第58卷第1期 2025-1 Estimated risk for transfusion of monkeypox contaminated perioperative blood transfusion: A call to action for stronger regulations and testing protocols
.........................
	第58卷第1期 2025-1 Insights into traumatic and crisis surgery: Implications of data analysis in conflict zones
.........................
	第58卷第1期 2025-1 Tongue peeling as an adverse reaction with use of micronized purified flavonoid: A case report
.........................
	第58卷第1期 2025-1 Pilonidal sinus of scrotum: A rare clinical entity
.........................
	第58卷第1期 2025-1 Incidental autopsy finding of retiform hemangioendothelioma of the spleen
.........................
	第58卷第1期 2025-1 Retroperitoneal laparoscopy for hydronephrosis due to multiple fibroepithelial polyps: A case series
.........................

登入帳號才能閱讀全文

篇名	Purification and characterization of type AI arginase with immune inhibitory activity: Potential for the treatment of transplant rejection
作者	Soo-Ray Wang
卷期/出版年月	35卷2期 (2002/4)
頁次	59-66
摘要	A protein obtained from mammalian livers capable of inhibiting mitogen-induced lymphocyte proliferation, is called “liver-derived inhibitory protein”, or has been purified from mouse ;over homogenates and was proven to be arginase. Arginase in mammalian body has two isoforms, type I is liver orgin (i.e. LIP), type II exists in other tissues of the body. LIP can inhibit boyh Y- and B-lymphocytes. It is temperature stable up to 65℃ and PH stable from 3 to 11. LIP molecular weight is 105 kDa. The immune inhibitory property of liver arginase is due to arginine depletion resulting in suppression of syntheses of thymidine kinase and uridine kinase which have a half of only two hours; hence the DNA and RNA syntheses are inhibited and cell proliferation is suppressed. Liver arginase is the only mammalian amino acid-degradation enzyme that can potently inhibit lymphocyte proliferation. Because lymphocyte inhibition by liver arginase is reversible and is of non-cytotoxic, it is conceivable that liver arginase of human origin has a great potential of therapeutical benefit in treating transplant rejection.
關鍵詞
分類	Overview